Malaria Information and Prophylaxis, by Country [G]
| Country | Areas with Malaria | Drug Resistance2 | Malaria Species3 | Recommended Chemoprophylaxis4 | Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries |
|---|---|---|---|---|---|
| Gabon | All | Chloroquine | Primarily P. falciparum.
Less commonly, P. malariae, P. ovale, or P. vivax |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5 | |
| Gambia, The | All | Chloroquine | Primarily P. falciparum.
Less commonly, P. malariae, P. ovale, or P. vivax |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5 | |
| Georgia | None | Not Applicable | Not Applicable | Not Applicable | |
| Germany | None | Not Applicable | Not Applicable | Not Applicable | |
| Ghana | All | Chloroquine | Primarily P. falciparum.
Less commonly, P. malariae, P. ovale, or P. vivax |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine 5 | |
| Gibraltar (U.K.) | None | Not Applicable | Not Applicable | Not Applicable | |
| Greece | Rare local transmission May-November associated with imported malaria cases, in agricultural areas. None in tourist areas. | Not Applicable | P. vivax 100% | None | |
| Greenland (Denmark) | None | Not Applicable | Not Applicable | Not Applicable | |
| Grenada | None | Not Applicable | Not Applicable | Not Applicable | |
| Guadeloupe, including St. Barthélemy and Saint Martin (France) | None | Not Applicable | Not Applicable | Not Applicable | |
| Guam (U.S.) | None | Not Applicable | Not Applicable | Not Applicable | |
| Guatemala | Primarily in the provinces of Alta Verapaz, Escuintla, Izabal, Peten, Quiche, and Suchitapequez.
Few cases reported in other provinces. None in Antigua, Guatemala City, or Lake Atitlan. |
None | P. vivax 99%,
P. falciparum 1% |
Provinces of Alta Verapaz, Escuintla, Izabal, Peten, Quiche, and Suchitapequez: Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine,5 or tafenoquine5.
All other areas with malaria: None (mosquito avoidance only)6
|
1) City(ies) of travel 2) Province(s) of travel 3) Altitude of city(ies) of travel To determine if a city is within a certain provinceexternal icon Provinces of Guatemalaexternal icon Altitude informationexternal icon |
| Guinea | All | Chloroquine | Primarily P. falciparum.
Less commonly, P. malariae, P. ovale, or P. vivax |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5 | |
| Guinea-Bissau | All | Chloroquine | Primarily P. falciparum.
Less commonly, P. malariae, P. ovale, or P. vivax |
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5 | |
| Guyana | All areas. Rare cases in the cities of Amsterdam and Georgetown. | Chloroquine | P. vivax 60%; P. falciparum 40% | All areas except the cities of Amsterdam and Georgetown: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Cities of Amsterdam and Georgetown: None (mosquito avoidance only)6
|
1) City(ies) of travel 2) Altitude of city(ies) of travel Altitude informationexternal icon for Guyana Map of Guyanaimage iconexternal icon |
1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources. Where proportions are not available, the primary species and less common species are identified.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Before prescribing primaquine or tafenoquine, patients must be screened for G6PD deficiency using a quantitative test.
6. Mosquito avoidance includes applying topical mosquito repellant, sleeping under an insecticide treated bed net, and wearing protective clothing (e.g., long pants and socks, long sleeve shirt). For additional details on mosquito avoidance, see: https://www.cdc.gov/malaria/travelers/index.html
7. P. knowlesi is a malaria species with a simian host (macaque). Human cases have been reported from most countries in Southeast Asia and are associated with activities in forest or forest-fringe areas. This species of malaria has no known resistance to antimalarials.